Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Brexanolone · Zulresso, LPCN 1154A

Small molecule · Modulator of GABA-A receptor · developed by Sage Therap Supernus

Approved FDA, Mar 2019
SUPN Developer
6 Registered trials

What is Brexanolone?

Brexanolone is a neuroactive steroid that acts as a positive allosteric modulator of GABA-A receptors.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as
Zulresso, LPCN 1154A, SAGE-547, SGE-102, ZULRESSO, Allopregnanolone
Drug type
Small molecule
Targets
GABA-A receptor
Mechanism
Modulator of GABA-A receptor
Pathways
GABAergic neurotransmission
Therapy area
Psychiatry
Developer
Sage Therap Supernus (SUPN)
Also in trials of
LPCN
FDA status
Approved as Zulresso (March 19, 2019), NDA211371 · FDA label
UNII
S39XZ5QV8Y

✅ FDA-approved uses

From the indications section of the FDA label (version of Dec 31, 2024). Read the full label for the exact wording, limitations and safety information.

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT05059600 Phase 4 Postpartum Depression Completed SUPN
NCT07822321 Phase 3 Depression, Postpartum Recruiting LPCN
NCT03665038 Phase 3 Post Partum Depression Completed SUPN
NCT02942004 Phase 3 Postpartum Depression Completed SUPN
NCT02477618 Phase 3 Super-Refractory Status Epilepticus Completed SUPN
NCT03924492 N/A Postpartum Depression Approved for marketing SUPN

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Depression, PostpartumPeripartum DepressionPost-Natal DepressionPost-partum DepressionPostnatal DepressionPostpartum Depression (PPD)Postpartum DepressionSuper-Refractory Status Epilepticus

More from Sage Therap Supernus

Sources

Updated Nov 1, 2026. Something wrong or missing? Report it on the SUPN page.

Follow SUPN, the company behind Brexanolone

See SUPN's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

SUPN catalysts and pipeline →
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.